Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Kinetics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and duration.

Unett DJ, Gatlin J, Anthony TL, Buzard DJ, Chang S, Chen C, Chen X, Dang HT, Frazer J, Le MK, Sadeque AJ, Xing C, Gaidarov I.

J Pharmacol Exp Ther. 2013 Dec;347(3):645-59. doi: 10.1124/jpet.113.207670.

2.

Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.

Song J, Hanniford D, Doucette C, Graham E, Poole MF, Ting A, Sherf B, Harrington J, Brunden K, Stricker-Krongrad A.

Assay Drug Dev Technol. 2005 Dec;3(6):649-59.

PMID:
16438660
3.

S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.

Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G.

J Pharmacol Exp Ther. 2012 Mar;340(3):750-64. doi: 10.1124/jpet.111.187468.

4.

Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy.

Cavero I, Guillon JM.

J Pharmacol Toxicol Methods. 2014 Mar-Apr;69(2):150-61. doi: 10.1016/j.vascn.2013.12.004. Review.

PMID:
24361689
5.

Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.

Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ.

Br J Pharmacol. 1999 Sep;128(1):13-20.

6.

Ras involvement in signal transduction by the serotonin 5-HT2B receptor.

Launay JM, Birraux G, Bondoux D, Callebert J, Choi DS, Loric S, Maroteaux L.

J Biol Chem. 1996 Feb 9;271(6):3141-7.

7.

The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.

Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP.

Br J Pharmacol. 2004 Nov;143(5):549-60.

8.

[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor.

Wainscott DB, Sasso DA, Kursar JD, Baez M, Lucaites VL, Nelson DL.

Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):17-24.

PMID:
9459568
9.

Predictability of peripheral lymphocyte reduction of novel S1P1 agonists by in vitro GPCR signaling profile.

Xu H, McElvain M, Fiorino M, Henkle B, Sherman L, Xu Y, Tominey E, Kelley K, Adlam M, Bürli R, Siu J, Wong M, Cee VJ.

J Biomol Screen. 2013 Oct;18(9):997-1007. doi: 10.1177/1087057113488629.

PMID:
23686102
10.

beta-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1.

van Der Lee MM, Bras M, van Koppen CJ, Zaman GJ.

J Biomol Screen. 2008 Dec;13(10):986-98. doi: 10.1177/1087057108326144.

PMID:
19036707
11.

Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.

Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L.

Br J Pharmacol. 2003 Sep;140(2):277-84.

12.
13.
14.
15.

Molecular determinants and feedback circuits regulating type 2 CRH receptor signal integration.

Markovic D, Punn A, Lehnert H, Grammatopoulos DK.

Biochim Biophys Acta. 2011 May;1813(5):896-907. doi: 10.1016/j.bbamcr.2011.02.005.

16.

Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation.

Li B, Zhang S, Zhang H, Nu W, Cai L, Hertz L, Peng L.

Psychopharmacology (Berl). 2008 Dec;201(3):443-58. doi: 10.1007/s00213-008-1306-5.

PMID:
18758753
17.

Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance.

Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW.

J Pharmacol Exp Ther. 2010 Dec;335(3):572-9. doi: 10.1124/jpet.110.173005.

18.
19.

Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves.

Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE.

J Pharmacol Exp Ther. 2003 Jan;304(1):229-37.

20.

CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.

Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, McAllister S, Strange PG, Stephens GJ, Pertwee RG, Ross RA.

Mol Pharmacol. 2013 Feb;83(2):322-38. doi: 10.1124/mol.112.080879.

Items per page

Supplemental Content

Support Center